Super-Pharm Slashes iPhone 17 Price Amidst Retailer Price War
Translated & summarized from Ice by baba
Super-Pharm has launched the iPhone 17 (256GB, eSIM) for 2,799 shekels, intensifying a price war among Israeli retailers. The device is available online and for pickup, featuring free shipping and a one-year warranty. This move follows the retailer's recent offering of the iPhone 18 Pro Max at a competitive price.
The story in 5 lines · by baba
- Super-Pharm is selling the iPhone 17 (256GB) for 2,799 shekels amidst a price war.
- The iPhone 17 model features eSIM, parallel import, and is available in five colors.
- The special price is currently limited to online orders or pre-arranged pickup.
- The device includes a 6.3-inch screen, A19 chip, and a 48MP Fusion camera.
- Super-Pharm recently began selling the iPhone 18 Pro Max for 5,549 shekels.
Amidst an ongoing price war between major Israeli retailers over Apple iPhones, Super-Pharm announced Sunday it has begun selling the iPhone 17 with 256GB of storage for only 2,799 shekels. This model, featuring eSIM, is available through parallel import in five colors. It includes free standard shipping and a one-year warranty. The special price is currently offered exclusively through online orders or pre-arranged in-store pickup. The device boasts a 6.3-inch screen, the A19 chip, and a 48MP Fusion camera system. It is sold and supplied by Newcel, an external vendor on Super-Pharm's online platform, with Mobile CE providing the one-year warranty. Super-Pharm stated that home delivery takes 4-8 business days, while same-day pickup is possible with prior coordination. This follows Super-Pharm's recent entry into the competitive market with the iPhone 18 Pro Max (256GB, eSIM) offered at 5,549 shekels with free shipping.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Right 1Other 1
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
